Wearable Health Solutions Stock (OTC: WHSI)

Latest News for Wearable Health Solutions Stock (OTC:WHSI)

Wearable Health Solutions Inc is engaged in manufacturing medical alarm devices which are used to summon help in the event of an emergency. The company provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency devices, it provides wearable healthcare products, tracking services, and turn-key solutions that enable its users to be proactive with their health, as well as safe and protected.

WEARABLE HEALTH SOLUTIONS by Wearable Health Solutions, Inc

Wearable Health Solutions Inc

President Joe Biden announced on Thursday that his administration is officially moving <a href="https://www.benzinga.com/cannabis">to reschedule marijuana</a> under federal law, while praising what he called a &#8220;monumental&#8221; step.
"Today my administration took a major step to reclassify marijuana from a schedule one drug to a schedule three drug. It's an important move toward reversing long-standing inequities. Today's announcement builds on the work we've already done, and it adds to the action we've taken to lift barriers to housing, employment, small business loans and so much more for tens of thousands of Americans," Biden said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Too many lives have been upended because of our failed approach to marijuana. So today, the <a href="https://twitter.com/TheJusticeDept?ref_src=twsrc%5Etfw">@TheJusticeDept</a> is taking the next step to reclassify marijuana from a Schedule I to a Schedule III drug under federal law. Here&#39;s what that means: <a href="https://t.co/TMztSyyFYm">pic.twitter.com/TMztSyyFYm</a>
&mdash; President Biden (@POTUS) <a href="https://twitter.com/POTUS/status/1791152464617431389?ref_src=twsrc%5Etfw">May 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Justice Dept. On The Move</h2>
The Justice Department is expected to post its proposed rules to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) in the Federal Register, a senior administration official said on Thursday. A 60-day public comment period will follow.
"Look folks, no one should be in jail for merely using or possessing marijuana. Period," the president said. "Far too many lives have been upended because of a failed approach to marijuana and I'm committed to righting those wrongs. You have my word on it."
The White House announcement comes several weeks after the Department of Justice confirmed the <a href="https://www.benzinga.com/markets/cannabis/24/04/38530190/breaking-dea-reportedly-moves-to-reschedule-cannabis-stocks-rise-sharply-on-the-news">DEA was moving to reclassify cannabis</a> as a Schedule III drug.
<h2 class="wp-block-heading">Cannabis Stocks Rose On The News</h2>
Following the historic announcement, cannabis stocks quickly reacted with AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) trading up 7.54% at $10.34 per share at the time of writing. Another marijuana ETF, AdvisorShares Pure Cannabis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>), was up 5.41% at $4.4 per share.
Popular weed giants, Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) were trading 15.35% higher at $11.43 per share and 11.10% at $7.91 per share, respectfully.
Curaleaf Holdings (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX">CURLF</a>) was slightly up, trading 5.98% higher at $5.95 per share, and one of the biggest cannabis players in Canada and the US, Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) was trading just a bit higher or $6.75% with $2.21 per share.
Now Read: <a href="https://www.benzinga.com/markets/cannabis/24/05/38878750/mike-tysons-cannabis-products-available-in-even-more-dispensaries-in-colorado-via-new-partnershi">Mike Tyson&#8217;s Cannabis Products Available In &#8216;Even More Dispensaries&#8217; In Colorado Via New Partnership, Here&#8217;s Where To Find Them</a>
Photo: Shutterstock

Cannabis

News

Politics

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

MSOS

TLRY

YOLO

Biden Announces 'Monumental' Marijuana Rescheduling, DOJ To Take Next Steps

Ratings for Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Praxis Precision Medicine, presenting an average target of $116.43, a high estimate of $150.00, and a low estimate of $105.00. This current average has increased by 3.49% from the previous average price target of $112.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882509_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Praxis Precision Medicine is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$117.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Kambiz Yazdi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$128.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Praxis Precision Medicine. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Praxis Precision Medicine compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Praxis Precision Medicine's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Praxis Precision Medicine's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Praxis Precision Medicine analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Praxis Precision Medicine's Background</h2>
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
<h3>Praxis Precision Medicine: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3 months period, Praxis Precision Medicine faced challenges, resulting in a decline of approximately -36.9% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Praxis Precision Medicine's net margin excels beyond industry benchmarks, reaching -9177.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -26.43%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Praxis Precision Medicine's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -23.38%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Praxis Precision Medicine's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

PRAX

Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Coupang, presenting an average target of $25.86, a high estimate of $32.00, and a low estimate of $21.00. This current average has increased by 19.89% from the previous average price target of $21.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882489_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Coupang by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennifer Han</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Jiong Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Yu</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>John Yu</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Shao</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Peter Milliken</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$18.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coupang. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Coupang compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Coupang's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Coupang's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CPNG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coupang analyst ratings.</a>
<h2>All You Need to Know About Coupang</h2>
Coupang Inc is an e-commerce company. It sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Developing Offerings. The company generates maximum revenue from the Product Commerce segment. Product Commerce includes core retail (owned inventory) and marketplace offerings (third-party merchants) and Rocket Fresh, fresh grocery offering, as well as advertising products associated with these offerings.
<h3>Coupang: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Coupang showcased positive performance, achieving a revenue growth rate of 22.63% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Coupang's net margin is impressive, surpassing industry averages. With a net margin of 0.07%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Coupang's ROE stands out, surpassing industry averages. With an impressive ROE of 0.12%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Coupang's ROA stands out, surpassing industry averages. With an impressive ROA of 0.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Coupang adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPNG

The Analyst Landscape: 7 Takes On Coupang

Ratings for Caribou Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBU#NASDAQ">CRBU</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Caribou Biosciences, presenting an average target of $21.5, a high estimate of $24.00, and a low estimate of $19.00. A decline of 6.52% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882482_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Caribou Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$19.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Caribou Biosciences. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Caribou Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Caribou Biosciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Caribou Biosciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CRBU/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Caribou Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Caribou Biosciences</h2>
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
<h3>Caribou Biosciences's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Caribou Biosciences's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -30.64% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Caribou Biosciences's net margin excels beyond industry benchmarks, reaching -1697.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -11.59%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Caribou Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.83%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.08, Caribou Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRBU

Expert Ratings For Caribou Biosciences

In the last three months, 6 analysts have published ratings on Starwood Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Starwood Prop Trust, presenting an average target of $21.58, a high estimate of $23.00, and a low estimate of $20.00. Observing a downward trend, the current average is 1.15% lower than the prior average price target of $21.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882433_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Starwood Prop Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Laws</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$23.00</td>
<td>$23.50</td>
</tr>
<tr>
<td>Sarah Barcomb</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Starwood Prop Trust. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Starwood Prop Trust compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Starwood Prop Trust's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Starwood Prop Trust's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/STWD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Starwood Prop Trust analyst ratings.</a>
<h2>Delving into Starwood Prop Trust's Background</h2>
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment and Investing and Servicing Segment. The company generates the majority of its revenue from the Real estate commercial and residential lending segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
<h3>Starwood Prop Trust: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Starwood Prop Trust showcased positive performance, achieving a revenue growth rate of 88.48% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Starwood Prop Trust's net margin is impressive, surpassing industry averages. With a net margin of 50.5%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Starwood Prop Trust's ROE stands out, surpassing industry averages. With an impressive ROE of 2.42%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.22%, the company showcases effective utilization of assets.
Debt Management: Starwood Prop Trust's debt-to-equity ratio is below the industry average at 1.44, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STWD

A Closer Look at 6 Analyst Recommendations For Starwood Prop Trust

Raymond James analyst Steven Seedhouse upgrades Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) from Outperform to Strong Buy and raises the price target from $115 to $116.

Upgrades

Price Target

VKTX

Raymond James Upgrades Viking Therapeutics to Strong Buy, Raises Price Target to $116

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.04%. Currently, Welltower has a market capitalization of $61.15 billion. 
Buying $1000 In WELL: If an investor had bought $1000 of WELL stock 15 years ago, it would be worth $13,331.13 today based on a price of $102.28 for WELL at the time of writing.
<h3>Welltower's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715882425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

WELL

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today

In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.75, along with a high estimate of $60.00 and a low estimate of $19.00. Observing a 1558.33% increase, the current average has risen from the previous average price target of $3.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882421_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Precision BioSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Adjusts</td>
<td>Buy</td>
<td>$60.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Precision BioSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Precision BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Precision BioSciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Precision BioSciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DTIL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Precision BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Precision BioSciences: A Closer Look</h2>
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
<h3>Key Indicators: Precision BioSciences's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Precision BioSciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 100.27%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Precision BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 48.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Precision BioSciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 30.63%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Precision BioSciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.99%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.83.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTIL

Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)

ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 15 years by 14.36% on an annualized basis producing an average annual return of 26.99%. Currently, ASML Holding has a market capitalization of $365.66 billion. 
Buying $100 In ASML: If an investor had bought $100 of ASML stock 15 years ago, it would be worth $3,591.06 today based on a price of $926.68 for ASML at the time of writing.
<h3>ASML Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715882420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASML

$100 Invested In ASML Holding 15 Years Ago Would Be Worth This Much Today

In the preceding three months, 6 analysts have released ratings for Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Newmont, presenting an average target of $47.25, a high estimate of $54.00, and a low estimate of $43.50. Observing a downward trend, the current average is 4.87% lower than the prior average price target of $49.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1715882411_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Newmont among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bob Brackett</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Jackie Przybylowski</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Greg Barnes</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Greg Barnes</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$43.50</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Newmont. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Newmont compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Newmont's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Newmont's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Newmont analyst ratings.</a>
<h2>Delving into Newmont's Background</h2>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 6.9 million ounces of gold in 2024. However, after buying Newcrest, Newmont is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at end December 2023.
<h3>Newmont's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Newmont's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 50.17% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Newmont's net margin is impressive, surpassing industry averages. With a net margin of 4.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Newmont's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Newmont's ROA excels beyond industry benchmarks, reaching 0.31%. This signifies efficient management of assets and strong financial health.
Debt Management: Newmont's debt-to-equity ratio stands notably higher than the industry average, reaching 0.33. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Newmont: 6 Analysts Share Their Views

On the "Afford Anything" podcast, Suze Orman delivered a pointed critique on the notion of retiring early with a $2 million portfolio. She was direct in her advice, emphasizing the insufficiency of such an amount for early retirement. "Two million dollars is nothing," <a href="https://www.benzinga.com/personal-finance/24/02/37318402/you-are-going-to-burn-up-alive-suze-orman-hates-the-fire-movement-and-says-you-need-at-least-20-">Orman declared</a>, "It&#8217;s nothing. It&#8217;s pennies in today&#8217;s world, to tell you the truth."
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
</ul>
Orman expanded on the potential financial dangers that could deplete such savings quickly. "If you have $20 [million], $40 [million], $50 [million] or $100 million, be like me, okay. <a href="https://www.benzinga.com/personal-finance/24/04/38466698/are-you-saving-enough-to-be-in-the-top-3-of-retirees-heres-how-much-you-need">If you have that kind of money â€¦</a> and you want to retire, fine," she explained, contrasting this with the risks faced by those with less substantial sums. "But if you only have a few hundred thousand dollars, or a million, or $2 million, I&#8217;m here to tell you…if a catastrophe happens…what are you going to do? You are going to burn up alive."
Addressing the common retirement strategy of <a href="https://www.benzinga.com/personal-finance/24/05/38618728/suze-orman-calls-the-4-retirement-rule-very-dangerous-in-todays-challenging-economic-climate">withdrawing 4% annually</a>, Orman was skeptical: "I think that in the long run, $80,000, especially after taxes and as you get older, is not going to be enough. You may think it&#8217;s going to be enough, but it&#8217;s just not," she stated firmly.
Her advice underscores the importance of ample financial cushioning, particularly if unexpected costs arise, such as health care or family support needs. "Think about it logically," Orman urged, highlighting potential expenses that could easily top hundreds of thousands annually.&nbsp;
Trending: Reddit user reveals his retirement account&#8217;s &#8220;hourly wage&#8221; —<a href="https://www.benzinga.com/money/retirement-hourly-wage"> how much does your money really make per hour?</a>
When asked if $3 million was enough Orman firmly stated it was not. "If you don&#8217;t have at least $5 million or $10 million, don&#8217;t retire early," Suze asserted.&nbsp;
Orman&#8217;s assertion that individuals need "at least $5 million to retire early" stirred a mix of reactions, with some viewing it as excessively cautious while others validate her perspective.&nbsp;
Financial Samurai supports Orman&#8217;s viewpoint, highlighting that with today&#8217;s low interest rates, a larger capital is necessary to generate sufficient risk-adjusted income for early retirement. This is particularly relevant considering the need to depend more on investment income due to the diminishing reliability of traditional retirement income sources like Social Security and pensions.
While Orman faced significant backlash for her statements, with critics arguing that her figures are unattainable for most, the underlying principle she advocates is prudence.&nbsp;
This idea resonates with a segment of the financial community that sees the wisdom in ensuring a substantial financial buffer to address uncertainties in retirement, especially given potential long-term trends such as increasing health care costs and ongoing economic fluctuations. Orman's conservative approach, advocating for a higher threshold of retirement savings, reflects a cautious strategy designed to safeguard against the unknowns of future decades.
Financial planning is crucial for a secure retirement, and while Suze Orman&#8217;s recommendations may not be suitable for everyone, <a href="https://www.benzinga.com/money/fam">consulting a financial advisor</a> can help you craft a personalized plan that aligns with your unique goals and risk tolerance. An advisor can help you assess your current financial situation, including your income, expenses, debts, and savings, and create a road map to reach your retirement goals.
Read Next:
<ul>
<li>Boomers and Gen Z agree they need a salary of around $125,000 a year to be happy,<a href="https://www.benzinga.com/money/genz-salary-adv"> but millennials say they need how much?</a></li>
<li>Are you secretly doing better with your money than you think?<a href="https://www.benzinga.com/money/adv-financially-healthy"> Here are some signs you&#8217;re financially healthy.</a></li>
</ul>

Personal Finance

'$2 Million Is Nothing' Suze Orman Warns Don't Retire If You Don't Have At Least $5 Million Or $10 Million Saved

Ladenburg Thalmann analyst Jon Hickman upgrades Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) from Neutral to Buy and maintains the price target from $2 to $2.

WATT

Ladenburg Thalmann Upgrades Energous to Buy, Maintains Price Target to $2

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) saw a rise in its shares Thursday afternoon after experiencing a decline on Tuesday following the release of its <a href="https://www.benzinga.com/pressreleases/24/05/b38810094/alibaba-group-announces-march-quarter-2024-and-fiscal-year-2024-results">quarterly earnings report.</a>
Here's What's Going On: In terms of earnings, Alibaba&#8217;s quarterly performance was mixed. While revenue figures surpassed expectations of $30.4 billion by 1.08%, coming in at $30.729 billion, the company reported lower-than-expected EPS of $1.40 compared to estimates of $1.41 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
What&#8217;s New: Thursday&#8217;s positive movement may be partly due to an X <a href="https://twitter.com/CitronResearch/status/1791108355664085381">post</a> from Citron Research. The post expressed optimism about Alibaba&#8217;s future, highlighting its potential to emulate the successes of tech giants like Amazon and Microsoft in China. 
&#8220;Alibaba ($BABA) gaining momentum should cruise past $100,&#8221; Citron Research said.
Specifically, the firm pointed to Alibaba&#8217;s AI cloud prospects and strategic investments as key factors driving its growth. The post&#8217;s positive sentiment appears to have resonated with investors, contributing to the uptick in Alibaba&#8217;s stock price Thursday.
What Else: Barclays analyst Jiong Shao maintained an Overweight rating on Alibaba on Thursday, but lowered the price target from $109 to $107. Conversely, BofA Securities analyst Eddie Leung maintained a Buy rating on the stock and raised the price target from $99 to $103.
Overall, Thursday&#8217;s movement in Alibaba&#8217;s stock likely reflects a combination of factors, including the recent earnings report, a bullish tweet from Citron Research and analyst updates. Investors should continue to monitor Alibaba&#8217;s performance closely as it navigates challenges and opportunities in the Chinese market landscape.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38819576/whats-going-on-with-tilray-stock-tuesday">What&#8217;s Going On With Tilray Stock Tuesday?</a>
BABA Price Action: Alibaba shares are currently up 6.88% at $86.56 at publication time, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-1024x533.png" alt="" class="wp-image-342045" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16133201/BABA.png 1203w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Photo: zhu difeng from Shutterstock

Global

Movers

BABA

Alibaba Shares Bounce Back Thursday: What's Going On?

Bernstein analyst Bob Brackett maintains Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Market Perform and lowers the price target from $46 to $45.

Bernstein Maintains Market Perform on Newmont, Lowers Price Target to $45

A major trend shift is unfolding in the bond market, as key Treasury yields are currently testing the support of the crucial 200-day moving average, following the release of benign economic data that has cemented investor bets on <a href="https://www.benzinga.com/markets/equities/24/05/38842603/us-inflation-falls-as-expected-in-april-bolsters-fed-rate-cut-bets">Federal Reserve rate cuts.</a>
Last month, the inflation rate calculated using the consumer price index (CPI) came in at 3.4% compared to the same month last year, down from 3.5% in March, and in line with the forecasted 3.4% increase. The &#8220;core&#8221; inflation rate, which excludes volatile energy and food prices, also matched estimates, falling from 3.8% to 3.6%.
April's inflation reading has raised hopes that the disinflation trend may restart after three consecutive higher-than-predicted CPI readings in the first quarter. 
In his recent comments, Federal Reserve Chair Jerome Powell downplayed concerns about a possible hike in interest rates, signaling that the next adjustment would likely be a reduction. However, he emphasized this cut might come later than the markets initially anticipated.
Money markets are currently factoring in a 50 basis point reduction in interest rates by the end of the year, with a 70% chance for the Federal Reserve to begin its loosening cycle in September.
<h1 class="wp-block-heading">Treasury Yields Eye 200-Day Moving Average Support</h1>
The yield on the benchmark 10-year Treasury note traded at around 3.36% on Thursday, hitting an intraday low of 3.31%, temporarily sliding below the 200-day average positioned at 3.33%. 
Similarly, yields on both 2-year and 30-year Treasury notes are currently testing the support of the 200-day average.
The 200-day moving average is a widely watched technical indicator that helps investors gauge the long-term trend of a security or index. 
When Treasury yields fall below this level, it often signals a bearish or downward trend, suggesting that investors are seeking safer assets amid expectations of a slowing economy or lower interest rates. This shift can create a more favorable environment for bond prices, which move inversely to yields.
Here&#8217;s a snapshot of the current yield levels compared to their 200-day moving averages, as well as their 2024 high-to-low range. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Maturity</th>
<th>Current Yield</th>
<th>200-day Moving Average</th>
<th>2024 Peak</th>
<th>2024 Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 year</td>
<td>4.78%</td>
<td>4.75%</td>
<td>5.05%</td>
<td>4.12%</td>
</tr>
<tr>
<td>5 year</td>
<td>4.39%</td>
<td>4.35%</td>
<td>4.75%</td>
<td>3.75%</td>
</tr>
<tr>
<td>10 year</td>
<td>4.36%</td>
<td>4.33%</td>
<td>4.74%</td>
<td>3.82%</td>
</tr>
<tr>
<td>30 year</td>
<td>4.50%</td>
<td>4.48%</td>
<td>4.85%</td>
<td>4.07%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated as of May 16, 2024 (11:45 a.m. EDT) </figcaption></figure>
<h1 class="wp-block-heading">Chart: Inflation Data Casts Doubt On 10-Year Treasury Yield&#8217;s 2024 Rising Trend</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70-1024x495.png" alt="" class="wp-image-341796" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/05/16112728/image-70.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/05/38873168/us-inflation-data-prematurely-released-by-accident-yet-traders-missed-golden-oppo">US Inflation Data Prematurely Released By Accident, Yet Traders Missed Golden Opportunity</a>
<h1 class="wp-block-heading">Bond ETFs Set To Rally</h1>
The shift in Treasury yields has set the stage for a rally in bond ETFs, especially those focused on long-duration bonds. 
Here are five bond ETFs poised to benefit from rising expectations of Fed rate cuts:
<ol>
<li>iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>): This ETF tracks long-term U.S. Treasury bonds and is particularly sensitive to changes in interest rates. With long-dated yields falling, TLT could see sharp gains as it moves inversely to yields. In reaction to April&#8217;s inflation data, it rose 1.4% on the day.</li>
<li>Vanguard Total Bond Market Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BND#NYSE">BND</a>): A broader option, BND includes a mix of short-, medium-, and long-term bonds. Its diversified approach makes it a stable choice as market sentiments shift. Following the latest inflation statistics, BND inched 0.6% higher.</li>
<li>iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LQD#NYSE">LQD</a>): As rate cut expectations strengthen, investment-grade corporate bonds could see price increases. LQD offers exposure to this segment.</li>
<li>SPDR Bloomberg High Yield Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNK#NYSE">JNK</a>): Higher risk and higher reward, JNK covers the high-yield, or &#8220;junk,&#8221; bond market. Rate cuts often boost these bonds as investors hunt for yield.</li>
<li>iShares J.P. Morgan USD Emerging Market Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMB#NYSE">EMB</a>): As Treasury yields retreat and the Fed hints at a slower pace for rate hikes, emerging markets bonds could benefit from increased investor appetite for higher-yielding assets. Notably, EMB rose 1.1% on Wednesday, positively reacting to inflation data. </li>
</ol>
Read Now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38850154/economists-react-to-inflation-retail-sales-the-soft-landing-narrative-is-still-a-po">Economists React To Inflation, Retail Sales: &#8216;The Soft Landing Narrative Is Still A Possibility But Not A Guarantee&#8217;</a>
Photo: Shutterstock

Macro Notification

Bonds

Specialty ETFs

Treasuries

Econ #s

Federal Reserve

ETFs

iShares JPMorgan USD Emerging Markets Bond Fund

iShares Trust Barclays 20+ Year Treasury Bond Fund

Disinflation Hopes Reshape Treasury Yields' Major Trend: 5 Bond ETFs Poised To Rally On Fed Rate Cuts

Aiden Pleterski, who dubbed himself the &#8220;Crypto King,&#8221; has been arrested following a <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36698244/over-99-of-cryptocurrency-on-chain-is-legal-bitcoin-use-in-criminal-activity-falls-again">comprehensive 16-month investigation</a> by the Durham Regional Police Service (DRPS).
What Happened: Pleterski, a 25-year-old resident of Whitby, faces charges of Fraud Over $5000 and Laundering Proceeds of Crime.
The investigation began in July 2022 when the DRPS received numerous complaints from individuals claiming they had been defrauded by Pleterski. 
<a href="https://www.drps.ca/news/self-proclaimed-crypto-king-arrested/">According </a>to police, Pleterski presented himself as a savvy investor who could generate large weekly profits. Victims entrusted him with their money, expecting significant returns on their investments. However, they were ultimately unable to recover their funds.
&#8220;Victims provided money to him under similar circumstances, with the expectation that he was investing it on their behalf and would be returning them large profits,&#8221; the DRPS stated. &#8220;These victims were ultimately defrauded as well, and unable to recover their funds.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38878472/before-you-trust-another-crypto-guru-read-this-studys-results">Before You Trust Another Crypto Guru, Read This Study&#8217;s Results</a>
During the course of the investigation, police also identified another individual, Colin Murphy, aged 27 from Oshawa, who was allegedly involved in similar fraudulent activities. 
Murphy has been charged with Fraud Over $5000 and has been released on an Undertaking.
Further details of the case are expected to be disclosed at a press conference scheduled for Friday at noon, at 480 Taunton Road East in Whitby.
Pleterski has been held for a bail hearing, while Murphy, following his charge, has been released under specific conditions.
What&#8217;s Next: The evolving landscape of digital assets and the importance of regulatory frameworks will be central themes at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
This event aims to address the challenges and opportunities in the digital assets space, offering insights into the role of regulation in protecting investors and <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38875939/morgan-stanley-declares-270m-investment-into-bitcoin-etfs-in-q1-leads-institutional-inflow">ensuring market integrity.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38877709/cme-group-eyes-bitcoin-trading-amid-surging-wall-street-demand">CME Group Eyes Bitcoin Trading Amid Surging Wall Street Demand</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Ontario's 'Crypto King' Aiden Pleterski Arrested For Alleged Investment Fraud

Lake Street analyst Frank Takkinen downgrades Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) from Buy to Hold and lowers the price target from $10 to $2.

Downgrades

NOTV

Lake Street Downgrades Inotiv to Hold, Lowers Price Target to $2

Financial giants have made a conspicuous bullish move on Fair Isaac. Our analysis of options history for Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $459,930, and 4 were calls, valued at $184,422.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1120.0 to $1450.0 for Fair Isaac over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Fair Isaac's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Fair Isaac's substantial trades, within a strike price spectrum from $1120.0 to $1450.0 over the preceding 30 days.
<h3>Fair Isaac Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715881975_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$88.0</td>
<td>$80.7</td>
<td>$83.96</td>
<td>$1300.00</td>
<td>$243.0K</td>
<td style="text-align: right;">29</td>
<td style="text-align: right;">28</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$99.0</td>
<td>$91.3</td>
<td>$94.64</td>
<td>$1330.00</td>
<td>$132.4K</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">14</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$286.0</td>
<td>$278.6</td>
<td>$281.93</td>
<td>$1170.00</td>
<td>$56.3K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$278.0</td>
<td>$268.8</td>
<td>$273.86</td>
<td>$1120.00</td>
<td>$54.7K</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$222.0</td>
<td>$216.3</td>
<td>$216.32</td>
<td>$1310.00</td>
<td>$43.2K</td>
<td style="text-align: right;">29</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>

<h3>About Fair Isaac</h3>
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
After a thorough review of the options trading surrounding Fair Isaac, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Fair Isaac</h3>
<ul>
<li>With a volume of 127,318, the price of FICO is up 2.07% at $1396.48. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About Fair Isaac</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $1472.6666666666667.
<ul>
<li>An analyst from Raymond James persists with their Outperform rating on Fair Isaac, maintaining a target price of $1418. </li>
<li>An analyst from Needham downgraded its action to Buy with a price target of $1500. </li>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $1500. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Fair Isaac with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

FICO

This Is What Whales Are Betting On Fair Isaac

Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) reported a significant decline in crypto trading volumes for April, reflecting a broader <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38864022/robinhood-launches-its-first-crypto-staking-offering-for-solana-but-feature-limited-to-eur">cooling in retail investor</a> interest in digital assets.
What&#8217;s Next: The trading platform revealed in an operating report on Wednesday that its crypto notional trading volumes dropped to $10.1 billion in April, a steep 57% decrease from March&#8217;s $23.6 billion, Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-05-16/robinhood-s-crypto-trading-volume-falls-faster-than-rival-exchanges?embedded-checkout=true">reported</a>.
Despite this sharp fall, the figures were still up 173% compared to the same period last year.
The company&#8217;s daily average revenue trades (DARTs), which indicate the number of trades per day that generated commissions, also saw a notable decrease. 
DARTs slipped 43% to approximately 400,000 trades, although this was still double the amount recorded in April 2023. Robinhood has yet to comment on these recent figures.
The decline in trading volumes at Robinhood was more pronounced than that observed on other cryptocurrency exchanges.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38870019/spot-bitcoin-etfs-pocket-303m-net-inflows-on-wednesday-stars-seem-to-be-aligning-on-this-b">Spot Bitcoin ETFs Pocket $303M Net Inflows On Wednesday: &#8216;Stars Seem To Be Aligning On This Breakout,&#8217; Analytics Firm Writes</a>
Why It Matters: According to data from researcher CCData, spot trading volumes on centralized exchanges such as Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Binance, and Kraken fell 32.6% to $2 trillion in April.
This marked the first decline in seven months, attributed to a decrease in investor demand following Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) retreat from its March record high.
The recent dip in crypto trading volumes highlights the volatility and changing dynamics within the digital assets market. As retail investor enthusiasm wanes, platforms like Robinhood are experiencing more significant impacts compared to their larger counterparts.
What&#8217;s Next: This shift in trading activity and its implications for the digital assets market will be a key topic at Benzinga&#8217;s Future of Digital Assets event on Nov. 19.
The event will explore the evolving landscape of digital assets, offering insights into investor behavior, regulatory challenges, and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38875939/morgan-stanley-declares-270m-investment-into-bitcoin-etfs-in-q1-leads-institutional-inflow">future trajectory of cryptocurrencies.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38853012/crypto-traders-as-socially-valuable-as-escorts-to-brits-study-finds">Crypto Traders As Socially Valuable As Escorts To Brits, Study Finds</a>
Image: Shutterstock

$BTC

COIN

HOOD

Robinhood Crypto Trading Volume Slumped 57% In April

Guggenheim analyst Curry Baker maintains iHeartMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) with a Buy and lowers the price target from $5 to $3.

IHRT

Guggenheim Maintains Buy on iHeartMedia, Lowers Price Target to $3

Press Releases

Wearable Health Solutions Appoints Ambarish Gupta to Advisory Board

Wearable Health Solutions (WHSI) Files NPI to Enhance Health Information Exchange

Wearable Health Solutions Secures FCC Certification for Senior Device, Paving the Way for Production, Marketing, and Sales

Wearable Health Solutions' iHelp MAX (XWI-EC4WHS) Receives Prestigious PTCRB Certification, Securing Its Place Among Top-Performing Cellular Devices

Wearable Health Solutions, Inc. Settles $633,000 Legacy Debt at Significant Discount, Bolsters Financial Position for Future Growth

Wearable Health Solutions Inc.'s iHelp MAX Receives Approval from Industry Canada/IESD

Wearable Health Solutions to Advise Next Realm AI on Medical Internet of Things (MIoT) Solutions

Wearable Health Solutions (WHSI) is Ready to Produce iHelp Max 4G: A Next-Generation Mobile Medical Alert Device with 4G Connectivity, Fall Detection, and Geo-Fencing, Specially Designed for Senior Citizens